3 results
Sodium-glucose cotransporter 2 (SGLT2) inhibitors lead to a lowering of blood pressure and confer cardiovascular and renal protection in many, but not all people with type 2 diabetes (T2D), possibly due to a difference in sodium intake. with this…
Despite multifactorial treatment approaches residual risk for the development and progression of DKD remains high and novel therapies to halt renal burden in T2DM are urgently needed. SGLT-2 inhibitors are a relatively recent additions to the…
Objectives:Primary:- Assess safety and tolerability of PDC*lung01 vaccinations administered at two dose levels as single agent or during maintenance treatment by pemetrexed (for adenocarcinomas in Cohorts A1 and A2) or during treatment with anti-PD-…